Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxxinity, Inc. - Class A Common Stock (NQ: VAXX )

0.4694 +0.0514 (+12.30%)
Streaming Delayed Price Updated: 12:13 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 230,096
Open 0.4216
Bid (Size) 0.4610 (6)
Ask (Size) 0.4694 (1)
Prev. Close 0.4180
Today's Range 0.4200 - 0.5000
52wk Range 0.3911 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s disease 
From Vaxxinity, Inc.
Via GlobeNewswire
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
VAXX stock results show that Vaxxinity beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-44.43%
-44.43%
1 Month
-35.04%
-35.04%
3 Month
-36.06%
-36.06%
6 Month
-51.99%
-51.99%
1 Year
-77.86%
-77.86%

More News

Read More
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
From Vaxxinity, Inc.
Via GlobeNewswire
Recap: Vaxxinity Q3 Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
From Vaxxinity, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
From Vaxxinity, Inc.
Via GlobeNewswire
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Vaxxinity to Present at Upcoming Investor Conferences in September
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial
Via Benzinga
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.